GG's DD, oh & NoMo's 2

[GGraessle]

Press Release Source: Nova BioGenetics Inc.


Nova BioGenetics is Pleased to Announce Dr. Cecil Smith Has Joined the Company as Chief Executive Officer
Monday August 18, 9:26 am ET


ATLANTA--(BUSINESS WIRE)--Aug. 18, 2003--Nova BioGenetics Inc. (OTC Bulletin Board: NVBG - News) announces that Dr. Cecil Smith has joined the Company as its new CEO. Dr. Smith brings 25 years of experience in the microbial contamination control business. He is an internationally recognized expert in microbial decontamination strategies and biosafety. Dr. Smith has conducted research in the areas of antibiotic resistance and microbial adaptation, as well as managing clinical trials. One of his principal roles will be to extend the spectrum of molecules in the antibiotic resistance portfolio of NVBG.
About Nova BioGenetics:

Nova BioGenetics, Inc., ("Nova"), is a biopharmaceuticals company headquartered in Atlanta, Georgia. Nova is engaged in the discovery, development, and commercialization of new therapeutic agents that treat life-threatening infectious diseases. Nova BioGenetics' pipeline, for both FDA and EPA regulatory agencies, is based on patented technology and Nova's own initial bench studies, used as a broad base for applications with existing antibiotic compounds. Attaching the patented technology with antibiotic compounds has proven to facilitate potential disruption of bacterial agents thus producing new therapeutic agents to be marketed.

Further information on Nova and its line of products can be found by visiting the firm's web site at http://www.novabiogenetics.com, Ph.#770-650-6508, Fax #[phone], contact Tim Moses, Chairman, Director of Public Securities.

Safe Harbor/Forward-looking Statements:

These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in any forward-looking statements, all of which are difficult to predict and many of which are beyond the control of the company, including areas such as: developing technologies; dependence on collaborative partners; the inherent complexity and uncertainty regarding the development of products; early-stage development of Nova; the result of research and development efforts; future capital needs; uncertainty of additional funding; government regulations; and other factors which are detailed in the company's periodic reports and registration statements filed with the Securities and Exchange Commission. Nova does not undertake to revise or update any forward-looking statement to reflect events or circumstances that may arise after the date hereof.



--------------------------------------------------------------------------------
Contact:
Nova BioGenetics, Atlanta
Tim Moses, 770/650-6508
Fax: [phone]
http://www.novabiogenetics.com